These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15696221)

  • 1. [Scientific evidence and global conception of empirical treatment of lower respiratory tract infections in the community].
    Barberán J; Giménez MJ; Aguilar L; Prieto J
    Rev Esp Quimioter; 2004 Dec; 17(4):317-24. PubMed ID: 15696221
    [No Abstract]   [Full Text] [Related]  

  • 2. Community-acquired bacterial respiratory tract infections.
    Brunton S; Carmichael B; Fitzgerald M; Liu H; Varon J; Weiland D
    J Fam Pract; 2005 Mar; 54(3):255-62. PubMed ID: 15755379
    [No Abstract]   [Full Text] [Related]  

  • 3. [Management of community-acquired lower respiratory infections. Management in the hospital].
    Chidiac C
    Rev Mal Respir; 1999 Jan; 16 Suppl 3():S11-2. PubMed ID: 10088221
    [No Abstract]   [Full Text] [Related]  

  • 4. The continuing challenge of lower respiratory tract infections.
    Moellering RC
    Clin Infect Dis; 2004 May; 38 Suppl 4():S319-21. PubMed ID: 15127364
    [No Abstract]   [Full Text] [Related]  

  • 5. [Use of antibiotics in the treatment of community-acquired infections of the lower respiratory tract in the elderly].
    Sanguinetti CM
    Int J Clin Pract Suppl; 2000 Jan; (109):8-10. PubMed ID: 10765555
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel agents for the treatment of outpatient respiratory tract infections. Introduction.
    Pell DM
    Postgrad Med; 2002 Sep; 112(3 Suppl):5-6. PubMed ID: 19667592
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical and economic outcomes in the treatment of lower respiratory tract infections.
    Brixner DI
    Am J Manag Care; 2004 Oct; 10(12 Suppl):S400-7. PubMed ID: 15603249
    [No Abstract]   [Full Text] [Related]  

  • 8. Doxycycline in community acquired respiratory infections--a perspective of 1990's.
    Mahashur AA; Jaguste V
    J Assoc Physicians India; 1999 Mar; 47(3):326-31. PubMed ID: 10999130
    [No Abstract]   [Full Text] [Related]  

  • 9. [AFSSAPS guidelines for the antibiotic treatment of lower respiratory track infections].
    Agence Française de Sécurité Sanitaire des Produits de Santé
    Rev Mal Respir; 2003 Jun; 20(3 Pt 1):462-9. PubMed ID: 12910125
    [No Abstract]   [Full Text] [Related]  

  • 10. [Management of lower respiratory tract infections in immunocompetent adults (community-acquired pneumonia and acute exacerbation of chronic obstructive pulmonary disease): The challenge of a new consensus conference].
    Chidiac C
    Med Mal Infect; 2006; 36(11-12):535-7. PubMed ID: 17137740
    [No Abstract]   [Full Text] [Related]  

  • 11. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
    File TM
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S131-4. PubMed ID: 18029151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary care challenges in the management of respiratory tract infections.
    JAAPA; 2006 Sep; Suppl():4-14; quiz 15-6. PubMed ID: 17001773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriate antibiotic therapy for community-acquired respiratory tract infections.
    Gerbino PP; Brixner D; Sbarbaro J; Nicolau D
    Manag Care Interface; 2005 Dec; 18(12):41-8. PubMed ID: 16405224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical impact of antibiotic resistance in respiratory tract infections].
    Klugman K
    Med Mal Infect; 2007 Nov; 37 Spec No 1():6-10. PubMed ID: 18376503
    [No Abstract]   [Full Text] [Related]  

  • 15. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Sollet JP
    Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S113-4. PubMed ID: 16904296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.
    Blondeau JM; Tillotson G
    Int J Antimicrob Agents; 2008 Apr; 31(4):299-306. PubMed ID: 18276120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What drives our choices? Evidence, guidelines or habit?
    Lode H; Torres A; Cockle A
    Int J Antimicrob Agents; 2007 Feb; 29 Suppl 1():S17-22. PubMed ID: 17307652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ; Zhanel GG
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Summary: 15th Consensus conference on antimicrobial therapy for lower respiratory tract infections in immunocompetent adults].
    Rev Mal Respir; 2006 Sep; 23(4 Suppl):13S131-40. PubMed ID: 17057638
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.